Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy.
Mary-Keara BossM W DewhirstR S SampaioA BennettA TovmasyanK G BermanA W BeavenD A RizzieriI Batinic-HaberleM L HauckI SpasojevicPublished in: Cancer chemotherapy and pharmacology (2017)
We obtained critical information regarding the PK and toxicity of MnBuOE in dogs. The acute drug reaction and tachycardia post-injection have not been described in other species and may be specific to canines. The high tissue drug levels in lymph nodes have not been previously reported. MnBuOE accumulation in lymph nodes has important implications for the utility of adjuvant MnBuOE to treat lymphoma. With MnBuOE lymph node accumulation, reduction in the dose and/or administration frequency could be possible, leading to reduced toxicity.
Keyphrases
- lymph node
- early stage
- diffuse large b cell lymphoma
- sentinel lymph node
- neoadjuvant chemotherapy
- drug induced
- oxidative stress
- oxide nanoparticles
- liver failure
- respiratory failure
- adverse drug
- healthcare
- stem cells
- emergency department
- health information
- electron transfer
- catheter ablation
- intensive care unit
- radiation therapy
- cell therapy
- electronic health record
- social media
- quantum dots